
|Videos|October 31, 2017
Dr. Awan Discusses Combinations With Ibrutinib in CLL
Author(s)Farrukh Awan, MBBS
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.
Advertisement
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).
Combinations with ibrutinib have shown to be effective, but have not been proven to be superior to ibrutinib alone, says Awan.
The ALLIANCE trial compared ibrutinib to ibrutinib plus rituximab and chemoimmunotherapy, results of which could clarify the argument of monotherapy versus combination.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































